CMS May Clarify Drugs’ “Negotiated Price” To Address Cost Shifting In Part D
This article was originally published in The Pink Sheet Daily
CMS acknowledges its current definition of negotiated prices for drugs could be interpreted as permitting Medicare Part D plans to overstate them, which may move beneficiaries more quickly to the coverage gap and beyond, when beneficiaries, the government and drug firms incur greater responsibility for costs.
You may also be interested in...
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.